Literature DB >> 19621270

Features of central neurotransmission in animals in conditions of dietary magnesium deficiency and after its correction.

A A Spasov1, I N Iezhitsa, M S Kravchenko, M V Kharitonova.   

Abstract

Magnesium is important in the regulation of neurotransmitter metabolism and the modulation of receptor function in the CNS, including neurotransmitters and receptors involved in the pathogenesis of many mental disorders. The aim of the present work was to perform a pharmacological evaluation of the central mechanisms of action of magnesium salts in the clofelin, phenamine, arecoline, nicotine, apomorphine, and 5-hydroxytryptophan tests in conditions of dietary magnesium deficiency. After reaching the magnesium deficiency state, animals were given oral (via tube) magnesium L-asparaginate and magnesium chloride lone and in combination with vitamin B(6), as well as the reference agent Magne B6. Our assessments of phenamine stereotypy in magnesium-deficient animals showed reductions in the latent period by an average of 14.89% and a significant increase in the duration of phenamine stereotypy by an average of 19.44% (from 268.23 +/- 8.17 to 320.36 +/- 19.90 min) as compared with intact rats. Studies of hyperkinesia induced by 5-hydroxytryptophan showed a two-fold reduction in its extent in the magnesium-deficient group (p </= 0.05). Administration of arecoline to magnesium-deficient animals resulted in a statistically significant increase in the latent period from a mean of 92.75 +/- 19.35 to 245.17 +/- 121.86 sec, with a reduction in the duration of tremor from an average of 1175.58 +/- 127.87 to 703.83 +/- 89.33 sec (p </= 0.05) as compared with intact rats. In terms of its influence on the hypothermic effects of clofelin and apomorphine and the convulsive effect of nicotine, there were no significant differences between the intact group and the magnesium-deficiency animals. Administration of magnesium salts compensated for the magnesium deficiency in plasma and erythrocytes, which was accompanied by recovery of measures in the phenamine, arecoline, and 5-HT tests to levels typical of intact controls. There was a tendency for magnesium L-asparaginate and magnesium chloride combined with pyridoxine to have greater activity, and the efficacies of these treatments was no less than that of reference agent Magne B6. Thus, dietary magnesium deficiency led to impairment of neurotransmission in central serotoninergic, M-cholinergic, and noradrenergic structures and administration of magnesium salts reversed these changes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19621270     DOI: 10.1007/s11055-009-9182-y

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  28 in total

1.  Magnesium deficiency in chronic schizophrenia.

Authors:  J D Kanofsky; R Sandyk
Journal:  Int J Neurosci       Date:  1991-11       Impact factor: 2.292

2.  Effects of serotonergic agents on plasma prolactin levels in pyridoxine-deficient adult male rats.

Authors:  S K Sharma; K Dakshinamurti
Journal:  Neurochem Res       Date:  1994-06       Impact factor: 3.996

3.  Bioavailability of US commercial magnesium preparations.

Authors:  M Firoz; M Graber
Journal:  Magnes Res       Date:  2001-12       Impact factor: 1.115

Review 4.  Modulation of glutamate receptors: strategies for the development of novel antidepressants.

Authors:  P Skolnick
Journal:  Amino Acids       Date:  2002       Impact factor: 3.520

5.  Effect of magnesium deficiency on vitamin B2 and B6 status in the rat.

Authors:  E Planells; A Lerma; N Sánchez-Morito; P Aranda; J LLopis
Journal:  J Am Coll Nutr       Date:  1997-08       Impact factor: 3.169

6.  Plasma magnesium levels in a population of psychiatric patients: correlations with symptoms.

Authors:  G K Kirov; N J Birch; P Steadman; R G Ramsey
Journal:  Neuropsychobiology       Date:  1994       Impact factor: 2.328

7.  Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones.

Authors:  M L Mayer; G L Westbrook; P B Guthrie
Journal:  Nature       Date:  1984 May 17-23       Impact factor: 49.962

8.  Effect of various serotoninergically induced manipulations on audiogenic seizures in magnesium-deficient mice.

Authors:  P Bac; N Pages; C Herrenknecht; C Dewulf; P Binet; J Durlach
Journal:  Magnes Res       Date:  1994-06       Impact factor: 1.115

9.  A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients.

Authors:  G Chouinard; L Beauclair; R Geiser; P Etienne
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1990       Impact factor: 5.067

Review 10.  Magnesium and therapeutics.

Authors:  J Durlach; V Durlach; P Bac; M Bara; A Guiet-Bara
Journal:  Magnes Res       Date:  1994-12       Impact factor: 1.115

View more
  3 in total

Review 1.  Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis.

Authors:  James J DiNicolantonio; James H O'Keefe; William Wilson
Journal:  Open Heart       Date:  2018-01-13

Review 2.  Can Nutrients and Dietary Supplements Potentially Improve Cognitive Performance Also in Esports?

Authors:  Monika Szot; Ewa Karpęcka-Gałka; Remigiusz Dróżdż; Barbara Frączek
Journal:  Healthcare (Basel)       Date:  2022-01-18

3.  Correlation of Ionized Magnesium with the Parameters of Oxidative Stress as Potential Biomarkers in Patients with Anxiety and Depression: A Pilot Study.

Authors:  Ana Opanković; Srđan Milovanović; Branimir Radosavljević; Milena Čavić; Irina Besu Žižak; Zoran Bukumirić; Milan Latas; Branislava Medić; Sonja Vučković; Dragana Srebro; Katarina Savić Vujović
Journal:  Dose Response       Date:  2022-07-21       Impact factor: 2.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.